Literature DB >> 14498820

Reinforcement of counseling attendance and alcohol abstinence in a community-based dual-diagnosis treatment program: a feasibility study.

Todd C Helmus1, Karen K Saules, Eugene P Schoener, John M Roll.   

Abstract

This study evaluated the effectiveness of a community-based contingency management (CM) protocol reinforcing punctual dual-diagnosis group counseling attendance and negative breath alcohol levels. Participants were 20 dual-diagnosis patients. The A-B-A within-subjects reversal design included a 4-week baseline phase (BL), a 12-week CM intervention, and a 4-week return-to-baseline phase (R-BL). Group counseling was provided twice weekly, with breath tests before each session. CM attendance rates were significantly higher (65%+-28%) than BL (45%+-32%, p<.05) and remained elevated in the R-BL phase (68%+-29%). Despite clinical reports of frequent intoxication, during the study all breath test results were negative, regardless of study phase. Thus, no contingency effect on alcohol use could be determined. Results suggest that CM interventions can be effective in increasing attendance in a community treatment program for the dually diagnosed. (c) 2003 APA, all rights reserved

Entities:  

Mesh:

Year:  2003        PMID: 14498820     DOI: 10.1037/0893-164X.17.3.249

Source DB:  PubMed          Journal:  Psychol Addict Behav        ISSN: 0893-164X


  28 in total

1.  Contingency management for patients with dual disorders in intensive outpatient treatment for addiction.

Authors:  Thomas M Kelly; Dennis C Daley; Antoine B Douaihy
Journal:  J Dual Diagn       Date:  2014

Review 2.  Behavioral therapies for co-occurring substance use and mood disorders.

Authors:  Kathleen M Carroll
Journal:  Biol Psychiatry       Date:  2004-11-15       Impact factor: 13.382

3.  Interdependent group contingency management for cocaine-dependent methadone maintenance patients.

Authors:  Kimberly C Kirby; Marylouise E Kerwin; Carolyn M Carpenedo; Beth J Rosenwasser; Robert S Gardner
Journal:  J Appl Behav Anal       Date:  2008

4.  Voucher incentives increase treatment participation in telephone-based continuing care for cocaine dependence.

Authors:  Deborah H A Van Horn; Michelle Drapkin; Megan Ivey; Tyrone Thomas; Sarah W Domis; Oubah Abdalla; Daniel Herd; James R McKay
Journal:  Drug Alcohol Depend       Date:  2010-11-01       Impact factor: 4.492

5.  Experiences with SCRAMx alcohol monitoring technology in 100 alcohol treatment outpatients.

Authors:  Sheila M Alessi; Nancy P Barnett; Nancy M Petry
Journal:  Drug Alcohol Depend       Date:  2017-06-28       Impact factor: 4.492

6.  Effectiveness of Using Incentives to Improve Parolee Admission and Attendance in Community Addiction Treatment.

Authors:  Michael L Prendergast; Elizabeth A Hall; Jason Grossman; Robert Veliz; Liliana Gregorio; Umme S Warda; Kory Van Unen; Chloe Knight
Journal:  Crim Justice Behav       Date:  2015-07-10

7.  Objective continuous monitoring of alcohol consumption for three months among alcohol use disorder treatment outpatients.

Authors:  Sheila M Alessi; Nancy P Barnett; Nancy M Petry
Journal:  Alcohol       Date:  2019-01-31       Impact factor: 2.405

8.  A randomized study of cellphone technology to reinforce alcohol abstinence in the natural environment.

Authors:  Sheila M Alessi; Nancy M Petry
Journal:  Addiction       Date:  2013-01-30       Impact factor: 6.526

9.  Reinforcing integrated psychiatric service attendance in an opioid-agonist program: a randomized and controlled trial.

Authors:  Michael Kidorf; Robert K Brooner; Neeraj Gandotra; Denis Antoine; Van L King; Jessica Peirce; Sharon Ghazarian
Journal:  Drug Alcohol Depend       Date:  2013-07-15       Impact factor: 4.492

10.  Financial incentives to improve adherence to anti-psychotic maintenance medication in non-adherent patients - a cluster randomised controlled trial (FIAT).

Authors:  Stefan Priebe; Alexandra Burton; Deborah Ashby; Richard Ashcroft; Tom Burns; Anthony David; Sandra Eldridge; Mike Firn; Martin Knapp; Rose McCabe
Journal:  BMC Psychiatry       Date:  2009-09-28       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.